Developer docs
API playgroundTry for free, no card

Search company profiles

Cilian

Full company profile

uuid000lhgm

Namestring
Cilian
Legal namestring
Cilian AG
Websiteurl
cilian.de
Company typeenum
Private
Founded yearint
2001
Short descriptiontext

Cilian AG is a German biotechnology company that develops and commercializes a novel protein expression platform based on ciliates, serving biopharmaceutical and industrial biotech manufacturers seeking an alternative to conventional recombinant production hosts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMünster, Germany
HQ citystring
Münster
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
protein expression systems, ciliate biotechnology, recombinant proteins, biopharmaceutical manufacturing, biologics production
Industry1 code
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Chemical Manufacturing325
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Biotechnology / Protein Expression Services
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cilian AG develops and markets a novel protein expression system based on ciliates, providing an alternative recombinant protein production platform for the biopharmaceutical industry. The company's core technology uses ciliate organisms as expression hosts for producing recombinant proteins intended for use in biopharmaceutical manufacturing and research applications.

Differentiator
Functional benefit
Problem solved
No data
Peers10 records
TypeDirect peer
Description

Global biopharmaceutical CDMO and minority investor in Cilian. Comparable because Lonza operates the very protein expression and manufacturing services where Cilian's ciliate platform targets adoption.

TypeDirect peer
Description

Supplies bioprocessing technologies, expression systems, and services for recombinant protein production. Highly comparable because Cytiva's portfolio directly addresses the same protein expression workflow Cilian's platform targets.

TypeDirect peer
Description

Provides bioprocess equipment, filtration, and fermentation technologies used in recombinant protein manufacturing. Comparable because Sartorius serves the same downstream biomanufacturing customers evaluating alternative expression hosts.

TypeBroad incumbent
Description

Major life sciences incumbent offering protein expression reagents, cell lines, and CDMO services through its Gibco and Patheon brands. Comparable as a broad incumbent operating across expression systems and bioproduction.

5Merck KGaA (MilliporeSigma)
TypeBroad incumbent
Description

Life science tools and bioprocessing supplier offering cell lines, expression media, and process services. Comparable as a broad incumbent providing components for the same recombinant protein workflows.

TypeDirect peer
Description

Provides protein expression services and reagents across multiple host systems including mammalian, insect, and microbial. Comparable because GenScript competes in custom recombinant protein production that ciliate expression could address.

TypeEmerging player
Description

Synthetic biology company offering protein expression tools, gene synthesis, and proprietary expression platforms. Comparable as an emerging player developing alternative expression technologies for recombinant protein production.

TypeBroad incumbent
Description

Supplies proteins, reagents, and cell culture technologies used in research and bioprocess applications. Comparable as a broader incumbent whose protein and reagent catalog overlaps with the outputs of ciliate-based expression.

TypeBroad incumbent
Description

Industrial enzyme and microbial protein producer at very large scale. Comparable because Novonesis operates the large-scale alternative-host protein production that ciliate expression could potentially serve.

TypeEmerging player
Description

Specializes in plant cell culture-based production of recombinant proteins and APIs. Comparable as an emerging player using non-mammalian eukaryotic expression hosts for complex protein production.

Market position
Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cilian

Biotechnology / Protein Expression Servicescilian.de

Cilian AG is a German biotechnology company that develops and commercializes a novel protein expression platform based on ciliates, serving biopharmaceutical and industrial biotech manufacturers seeking an alternative to conventional recombinant production hosts.

Cilian firmographics

Firmographics
Name
Cilian
Legal name
Cilian AG
Website
https://cilian.de
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
1–10 employees
Short description
Cilian AG is a German biotechnology company that develops and commercializes a novel protein expression platform based on ciliates, serving biopharmaceutical and industrial biotech manufacturers seeking an alternative to conventional recombinant production hosts.
Ownership category
akta.pro rank

Cilian industry classification

Industry
Product category
Biotechnology / Protein Expression Services
NAICS
Chemical Manufacturing (325)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Protein expression systems
  • Ciliate biotechnology
  • Recombinant proteins
  • Biopharmaceutical manufacturing
  • Biologics production

Where Cilian is headquartered

Location

Headquarters

HQ city
Münster
HQ country
Germany
HQ region
Europe

Markets served

Cilian business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Cilian product offering

Product offering

Core offering

Cilian AG develops and markets a novel protein expression system based on ciliates, providing an alternative recombinant protein production platform for the biopharmaceutical industry. The company's core technology uses ciliate organisms as expression hosts for producing recombinant proteins intended for use in biopharmaceutical manufacturing and research applications.

Differentiator

Problem solved

Functional benefit

Companies that use Cilian

Customer profile

Ideal customer profiles2 records

Cilian technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Cilian competitors and assessment

Company assessment

Direct peers

  • Lonza Group: Global biopharmaceutical CDMO and minority investor in Cilian. Comparable because Lonza operates the very protein expression and manufacturing services where Cilian's ciliate platform targets adoption.
  • Cytiva: Supplies bioprocessing technologies, expression systems, and services for recombinant protein production. Highly comparable because Cytiva's portfolio directly addresses the same protein expression workflow Cilian's platform targets.
  • Sartorius AG: Provides bioprocess equipment, filtration, and fermentation technologies used in recombinant protein manufacturing. Comparable because Sartorius serves the same downstream biomanufacturing customers evaluating alternative expression hosts.
  • GenScript: Provides protein expression services and reagents across multiple host systems including mammalian, insect, and microbial. Comparable because GenScript competes in custom recombinant protein production that ciliate expression could address.

Broad incumbents

  • Thermo Fisher Scientific (Gibco): Major life sciences incumbent offering protein expression reagents, cell lines, and CDMO services through its Gibco and Patheon brands. Comparable as a broad incumbent operating across expression systems and bioproduction.
  • Merck KGaA (MilliporeSigma): Life science tools and bioprocessing supplier offering cell lines, expression media, and process services. Comparable as a broad incumbent providing components for the same recombinant protein workflows.
  • Bio-Techne: Supplies proteins, reagents, and cell culture technologies used in research and bioprocess applications. Comparable as a broader incumbent whose protein and reagent catalog overlaps with the outputs of ciliate-based expression.
  • Novonesis (formerly Novozymes): Industrial enzyme and microbial protein producer at very large scale. Comparable because Novonesis operates the large-scale alternative-host protein production that ciliate expression could potentially serve.

Emerging players

  • ATUM (formerly DNA2.0): Synthetic biology company offering protein expression tools, gene synthesis, and proprietary expression platforms. Comparable as an emerging player developing alternative expression technologies for recombinant protein production.
  • Phyton Biotech: Specializes in plant cell culture-based production of recombinant proteins and APIs. Comparable as an emerging player using non-mammalian eukaryotic expression hosts for complex protein production.

Market position

Customer concentration

Cilian social profiles

Digital presence

Cilian financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cilian leadership team

Management profile

Number of profiles

Profiles3 records

Cilian funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cilian M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cilian

What does Cilian do?

Cilian AG develops and markets a novel protein expression system based on ciliates, providing an alternative recombinant protein production platform for the biopharmaceutical industry. The company's core technology uses ciliate organisms as expression hosts for producing recombinant proteins intended for use in biopharmaceutical manufacturing and research applications.

When was Cilian founded?

Cilian was founded in 2001. It employs 1 to 10 people.

Where is Cilian based?

Cilian is headquartered in Münster, Germany, in the Europe region.

Who are Cilian's main competitors?

Direct peers on record are Lonza Group, Cytiva, Sartorius AG and GenScript. Broad incumbents are Thermo Fisher Scientific (Gibco), Merck KGaA (MilliporeSigma), Bio-Techne and Novonesis (formerly Novozymes). Emerging players are ATUM (formerly DNA2.0) and Phyton Biotech.

Does Cilian have an API?

No public API is recorded for Cilian.

What industry is Cilian in?

Cilian's product category is Biotechnology / Protein Expression Services. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales